Revvity, Inc. announced a value-added distribution agreement with SCIEX.
This strategic agreement is aimed at advancing mass spectrometry solutions in Revvity's newborn screening products. With this agreement, Revvity hopes to further help laboratories identify newborn babies with a range of rare disorders, from lysosomal storage disorders to amino acid disorders.
Revvity will combine SCIEX mass spectrometers with Revvity’s NeoBase 2 and NeoLSD reagents.